LPAR1 and systemic sclerosis: The LPA1 inhibitors BMS-986202/AM152 and BMS-986020 passed phase I and II clinical trials, respectively, for idiopathic pulmonary fibrosis; while the LPA1/3 inhibitor SAR 100842 passed a phase II clinical trial for systemic sclerosis [131].